Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prehabililtation in Retroperitoneal Sarcomas.

Journal of surgical oncology·2026
Same author

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

Nature communications·2026
Same author

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Nature communications·2026
Same author

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Augmented Reality Based 3D Modelling for Sentinel Lymph Node Localization in Cutaneous Melanoma: A Pilot Study.

Journal of surgical oncology·2026
Same author

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

相关实验视频

Updated: Sep 16, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

定义一个不可切除的初级逆皮肉瘤.

James Tai1, Eyal Mor1, Catherine Mitchell2,3

  • 1Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

ANZ journal of surgery
|July 10, 2025
PubMed
概括

大约12%的逆肌肉瘤 (RPS) 在呈现时是不可切除的. 定义可切除与不可切除的RPS可以改善患者的预后和管理策略.

关键词:
瘤学 在瘤学方面.辐射疗法 辐射疗法后皮质肉瘤是一种逆皮质肉瘤.手术 手术 手术 手术 手术 手术 手术血管 血管 血管 血管

更多相关视频

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.5K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K

相关实验视频

Last Updated: Sep 16, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.5K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K

科学领域:

  • 在瘤学瘤学.
  • 手术瘤学手术瘤学
  • 肉瘤研究研究 肉瘤研究

背景情况:

  • 逆皮质肉瘤 (RPS) 是一种罕见的,异质的介质细胞瘤.
  • 完全的宏观阻断切除是唯一的治愈治疗方法.
  • 对可切除与不可切除的RPS缺乏共识标准.

研究的目的:

  • 为了确定可切除和不可切除的初级RPS的速率.
  • 分析无法切除的原因.
  • 为了比较可切除和不可切除的RPS队列之间的结果.

主要方法:

  • 原发性非转移性RPS患者的回顾性分析 (2017年1月 - 2023年3月).
  • 可切除和不可切除组之间的患者和瘤细节的比较.
  • 分析导致不可切除的因素.

主要成果:

  • 分析了104名患者,91名 (87.5%) 可以切除,13名 (12.5%) 不能切除.
  • 在手术前 (53.8%) 或手术期间 (46.2%) 确定不切除性.
  • 最常见的原因是上层介质血管的干扰 (38.5%);不可切除的队列的死亡率更高 (84.6%与8.8%相比).

结论:

  • 大约12%的初级RPS呈现为不可切除的.
  • 术前成像通常可以识别不可切除的疾病.
  • 为了改善预后和管理,需要对可切除/不可切除RPS的清晰定义.